Michael Gwarisa In a move that could significantly reduce pill burden and improve adherence to antiretroviral therapy (ART), the United States Food and Drug Administration has approved a new once-daily pill developed by Merck & Co. for adults living with HIV-1 who are already virologically suppressed. The pill is intended to replace a patient’s existing